Mannan-Targeted Nanoparticles: Target Biology and Uptake

Introduction

Targeted drug delivery aims to move beyond simply administering a drug and instead improve where, how and by which cells the therapeutic payload is delivered. Among the emerging approaches, carbohydrate-functionalized nanoparticles are attracting increasing interest because naturally occurring carbohydrate–receptor interactions can be exploited for cellular recognition.

Mannan-targeted nanoparticles provide an important model for understanding this approach. Mannan and mannose-containing ligands can interact with carbohydrate-recognizing receptors, particularly the mannose receptor CD206, expressed prominently on macrophages and dendritic cells.

However, attaching a carbohydrate to a nanoparticle does not automatically create selective targeting. Successful targeting depends on receptor expression, ligand accessibility, multivalent interactions, nanoparticle properties, biological barriers and intracellular trafficking.

This article therefore examines the biological foundation of mannan/mannose targeting before addressing formulation and manufacturing considerations in later articles of this series.

1. Why Target Biology Matters

A targeted nanoparticle begins with a fundamental biological question: Which cells should receive the therapeutic payload, and which molecular features can distinguish those cells from others?

To answer this question, an effective target should ideally possess several characteristics:

• Adequate expression: It should be sufficiently expressed on the intended cell population.
• Accessibility: The target should be accessible from the extracellular environment.
• Sufficient receptor density: Its expression level should support meaningful ligand–receptor interactions.
• Specific ligand binding: It should enable effective recognition by the selected ligand.
• Internalization capacity: Following binding, the target should facilitate nanoparticle uptake into the cell.
• Appropriate intracellular trafficking: Once internalized, the nanoparticle should reach a compartment compatible with the intended drug-release mechanism.
• Acceptable expression in healthy tissues: Ideally, target expression in non-target tissues should be limited to reduce unintended uptake.
• Predictable expression across disease states: Target availability should remain sufficiently consistent across relevant disease stages and patient populations.

Therefore, target selection should precede ligand selection, because the biological properties of the target determine which ligand characteristics are required for effective recognition and uptake.

This distinction is particularly important in nanomedicine. Although ligand functionalization can enhance cellular recognition, a nanoparticle must first reach the biological environment containing the intended target. Before ligand–receptor recognition can occur, the nanoparticle must overcome several biological barriers, including circulation-related clearance, tissue distribution, protein adsorption and, where applicable, penetration through biological barriers. Consequently, successful targeting depends not only on ligand–receptor affinity but also on target accessibility, nanoparticle distribution and the subsequent cellular uptake process.

2. Mannan, Mannose and the Mannose Receptor

Mannan is a polysaccharide rich in mannose residues, whereas mannose is a monosaccharide. Although closely related, these terms should not be used interchangeably.

The biological rationale for mannose-based targeting is strongly associated with the mannose receptor, CD206, a C-type lectin receptor found prominently on macrophages and dendritic cells. In particular, its carbohydrate-recognition domains enable it to recognize suitable mannose-containing structures.

Accordingly, researchers have explored mannose, oligomannose, mannan derivatives and related carbohydrate structures as targeting ligands.

However, receptor recognition depends on more than the presence of mannose alone. Indeed, the chemical structure, spacing, orientation, valency and accessibility of the carbohydrate ligand can all influence receptor engagement.

3. From Ligand Recognition to Cellular Uptake

The basic targeting mechanism can be represented as:

Nanoparticle administration
↓
Biological distribution
↓
Encounter with target cell
↓
Ligand–receptor recognition
↓
Cell-surface association
↓
Receptor-mediated internalization
↓
Endosomal trafficking
↓
Intracellular drug release
↓
Pharmacological action

This sequence illustrates an important principle: binding is not the same as therapeutic delivery.

A nanoparticle may bind effectively to a receptor but still fail to achieve useful intracellular delivery if internalization, endosomal trafficking or payload release is inadequate.

Therefore, biological evaluation should measure more than total cell-associated fluorescence or nanoparticle uptake.

4. The Importance of Multivalency

One of the most interesting features of carbohydrate-targeted nanoparticles is multivalent recognition.

Although a single mannose molecule may interact relatively weakly with a receptor, a nanoparticle can present many ligand molecules simultaneously. Consequently, this arrangement may strengthen effective interactions through cooperative or multivalent binding.

The evidence matrix supporting this series includes studies examining carbohydrate clustering, ligand spacing and multivalent interactions. Moreover, the literature indicates that the spatial presentation of mannose or mannan derivatives can substantially influence receptor engagement.

Thus, ligand identity + ligand density + ligand spacing + ligand orientation can be more important than ligand identity alone.

This is a major design consideration for pharmaceutical R&D because, although increasing ligand density may improve targeting initially, the benefit may not continue indefinitely. Indeed, excessive surface modification can alter steric accessibility, protein interactions, colloidal properties and, ultimately, biological fate.

Macrophages are among the most investigated cellular targets for mannose-based nanomedicine.

The biological rationale is particularly relevant to diseases involving macrophage activity, including cancer, infectious diseases and inflammatory conditions. Tumor-associated macrophages, for example, can contribute to an immunosuppressive tumor microenvironment and have therefore become an important target for nanomedicine research.

Mannose-functionalized systems have consequently been investigated for delivering:

• Small-molecule drugs
• Nucleic acids
• Proteins
• Immunomodulatory agents
• Antimicrobial therapeutics
• Combination therapies

Recent research also explores macrophage reprogramming rather than simply delivering cytotoxic drugs.

This expands the concept from “drug targeting” toward “cell-state modulation.”

5. CD206 and Macrophage Targeting

Macrophages are among the most extensively investigated cellular targets in mannose-based nanomedicine.

This approach is particularly relevant to diseases involving macrophage activity, including cancer, infectious diseases and inflammatory conditions. For example, tumor-associated macrophages can contribute to an immunosuppressive tumor microenvironment and, consequently, have become important targets for nanomedicine research.

Accordingly, mannose-functionalized systems have been investigated for delivering:

• Small-molecule drugs
• Nucleic acids
• Proteins
• Immunomodulatory agents
• Antimicrobial therapeutics
• Combination therapies

Furthermore, recent research explores macrophage reprogramming rather than simply delivering cytotoxic drugs.

Thus, the concept extends beyond “drug targeting” toward “cell-state modulation.”

6. Beyond CD206: Other Biological Recognition Pathways

Although CD206 is central to mannan/mannose targeting, other biological pathways may also contribute to the activity of carbohydrate-functionalized nanoparticles.

For example, other carbohydrate-recognizing receptors and lectins can mediate cellular interactions, particularly in dendritic cells and other immune-cell populations.

Therefore, a formulation described as “mannose-targeted” should ideally specify:

Ligand → receptor → target cell → uptake pathway → intracellular destination

rather than simply claiming that the nanoparticle is “actively targeted.”

Consequently, this level of biological definition improves scientific interpretation and supports more robust translational development.

7. Protein Corona: The Hidden Biological Interface

After systemic administration, nanoparticles interact with cells differently from how they appear in the formulation vessel.

Indeed, proteins and other biomolecules can rapidly adsorb onto the nanoparticle surface, forming a dynamic protein corona. Consequently, this biological layer may alter apparent surface properties and potentially affect ligand accessibility and receptor recognition.

Thus, the effective targeting surface evolves through the following sequence:

Designed nanoparticle surface → biological environment → protein corona → cellular interface

This, in turn, creates an important translational challenge.

For example, a formulation demonstrating excellent receptor-specific uptake in a simplified cell culture system may behave differently in serum, animals or humans.

Therefore, biological targeting should be evaluated under progressively more physiologically relevant conditions.

8. Targeting Is a Balance Between Specificity and Accessibility

A highly specific receptor is not necessarily an ideal pharmaceutical target. Instead, it must also be accessible, sufficiently expressed and capable of supporting a useful biological response.

Moreover, several factors can reduce targeting efficiency:

Biological factor	Potential consequence
Low receptor expression	Limited cellular binding
Heterogeneous expression	Variable response
Poor ligand accessibility	Reduced receptor engagement
Protein corona formation	Altered targeting interface
Receptor recycling	Can influence intracellular exposure
Off-target expression	Reduced selectivity

Therefore, effective targeted nanomedicine requires integrated biological, formulation and pharmacological evaluation, rather than receptor specificity alone.

9. What the Literature Matrix Shows

The literature database assembled for this ProZBio series contains 47 peer-reviewed articles, reviews, patents and related sources covering 2016–2026. Overall, the evidence consistently links mannose/mannan targeting with CD206 biology, macrophage or antigen-presenting-cell targeting, multivalent recognition and nanoparticle uptake.

Furthermore, the matrix indicates that the field is progressing beyond simple ligand attachment toward more sophisticated control of ligand density, spatial arrangement, receptor engagement and computational optimization.

Additionally, several studies combine mannose with another targeting ligand, such as folate, to address multiple biological populations. Consequently, future targeting strategies may increasingly adopt multi-ligand architectures rather than rely on a single receptor.

However, these approaches also increase formulation complexity and, therefore, demand more rigorous characterization and biological validation.

10. Evidence Should Progress From Binding to Therapeutic Benefit

A scientifically robust development programme should progressively evaluate:

Target expression
→ Ligand binding
→ Competitive inhibition
→ Cellular uptake
→ Intracellular trafficking
→ Payload release
→ Pharmacological activity
→ In vivo biodistribution
→ Therapeutic benefit

This progression is essential because enhanced nanoparticle uptake alone does not necessarily demonstrate improved therapeutic efficacy.

Therefore, for pharmaceutical development, the strongest evidence emerges when receptor engagement can be linked to measurable improvements in drug exposure at the target site and, ultimately, to meaningful pharmacological or clinical outcomes.

11. Implications for Pharmaceutical R&D

For R&D scientists, the central lesson is that targeting should be treated as a biological design problem, rather than merely a formulation modification.

Accordingly, formulation scientists must consider ligand density, surface presentation and nanoparticle architecture together.

Meanwhile, pharmacologists should determine whether receptor engagement alters biodistribution, intracellular exposure and PK/PD relationships.

Similarly, for QA/QC and manufacturing teams, the biological target translates into measurable product attributes, including ligand identity, ligand density, conjugation efficiency, particle size and surface characteristics.

Ultimately, these attributes provide regulatory professionals with essential evidence to demonstrate product consistency and biological performance.

12. Where AI and Computational Biology Can Help

The growing complexity of ligand–receptor interactions creates opportunities for computational methods.

AI and molecular modelling can potentially support:

• Ligand–receptor interaction prediction
• Molecular docking
• Molecular dynamics simulations
• Ligand-density optimization
• Spacer-length selection
• Receptor-expression analysis
• Structure–activity relationships
• Prediction of cellular uptake
• Biodistribution modelling
• Selection of experimental conditions

The literature matrix includes examples of computational approaches used to examine ligand spacing, receptor interactions and nanoparticle design.

Nevertheless, AI predictions should remain hypothesis-generating and experimentally validated. A computationally predicted high-affinity interaction does not by itself establish biological selectivity or therapeutic benefit.

13. Key Challenges for Cellular Targeting

Despite strong research interest, several questions remain unresolved.

Target heterogeneity

CD206 expression can differ between tissues, disease states and patient populations.

Biological barriers

Circulation, tissue penetration and the protein corona can influence whether nanoparticles reach the intended receptor.

Ligand presentation

The same ligand can behave differently depending on density, orientation, spacer length and nanoparticle architecture.

In vitro–in vivo translation

Cell-culture uptake does not necessarily predict human biodistribution or therapeutic efficacy.

Biological complexity

Targeting one receptor may influence immune-cell behaviour, receptor recycling and intracellular trafficking in ways that are difficult to reproduce across models.

Therefore, the future of mannan-based targeting depends on better-defined biological mechanisms and stronger translational evidence, rather than simply increasing nanoparticle complexity.

14. Conclusion

Mannan/mannose targeting provides a valuable model for understanding how molecular recognition can be integrated with nanomedicine.

The central concept is straightforward:

Mannan or mannose ligand → receptor recognition → cellular uptake → intracellular delivery

However, successful pharmaceutical development is considerably more complex. Receptor biology, ligand structure, multivalency, surface presentation, protein corona, intracellular trafficking and disease-associated receptor expression must all be considered.

The next stage of this series therefore moves from “Why can the nanoparticle target the cell?” to “How can that targeting function be engineered reproducibly?”

Next Article

Article 2 — Mannan-Functionalized Nanoparticles: Conjugation, Surface Engineering and Formulation

The next article will examine ligand conjugation, linkers and spacers, surface engineering, ligand density, nanoparticle platforms and formulation strategies.

Frequently Asked Questions

1. What is the main target of mannan-based nanoparticles?

The mannose receptor CD206 is one of the principal targets investigated for mannose/mannan-functionalized delivery systems, particularly on macrophages and dendritic cells.

2. Are mannan and mannose the same?

No. Mannose is a monosaccharide, whereas mannan is a mannose-rich polysaccharide. Their biological and physicochemical behaviour can therefore differ.

3. How do targeted nanoparticles enter cells?

Depending on the receptor and nanoparticle system, ligand–receptor recognition can promote receptor-mediated endocytosis or other uptake mechanisms.

4. Does higher ligand density always improve targeting?

No. Targeting depends on ligand accessibility, spacing, orientation, receptor density and nanoparticle properties. More ligand is not necessarily better.

5. Does increased cellular uptake prove therapeutic efficacy?

No. Increased uptake is an important biological observation, but therapeutic benefit requires evidence connecting targeting with intracellular drug exposure, pharmacological response and, ultimately, meaningful in vivo or clinical outcomes.

6. Can AI improve mannan-targeted nanoparticle development? Potentially. AI and molecular modelling can support ligand selection, receptor interaction analysis, ligand-density optimization and prediction of biological behaviour, but experimental validation remains essential.

Disclaimer:

This article is intended for educational and scientific information purposes only. The discussion of mannan-targeted nanoparticles and receptor-mediated uptake reflects ongoing research and does not imply established clinical efficacy or regulatory approval. Formulation performance, safety, and therapeutic outcomes require appropriate experimental validation and regulatory assessment.